Sonoma Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the annual meeting of stockholders held on September 15, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol SNOA.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Shareholders voted on four proposals at the annual meeting. The total shares entitled to vote were 3,099,270, with 1,563,324 shares present or represented by proxy.
- Proposal 1 (Election of Director): Dr. Jay Birnbaum was elected as Class II Director with 277,332 votes for and 169,061 votes withheld.
- Proposal 2 (Say-on-Pay): Stockholders did not approve the advisory vote on executive compensation for the year ended March 31, 2022. Votes were 172,635 For, 223,644 Against, and 50,114 Abstain.
- Proposal 3 (Frequency of Say-on-Pay): Stockholders approved a frequency of "ONE YEAR" for future say-on-pay votes. Votes were 400,962 for One Year, 8,834 for Two Years, and 11,535 for Three Years.
- Proposal 4 (Auditor Ratification): Stockholders approved the ratification of Frazier & Deeter LLC as the independent registered public accounting firm for the fiscal year ending March 31, 2023. Votes were 1,505,708 For, 48,308 Against, and 9,308 Abstain.
Management Commentary and Risks
Management noted that while the say-on-pay vote is non-binding, the Board of Directors and Compensation Committee value the views of stockholders and will consider the outcome of the failed compensation vote when determining future compensation arrangements. No other risks, contingencies, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the company's response to the failed say-on-pay vote in future filings or press releases.
- Review the definitive proxy statement filed on July 22, 2022, for details on the executive compensation package that was rejected.
- Confirm the appointment of Frazier & Deeter LLC as the auditor for the upcoming fiscal year.
- Check subsequent filings for any changes to the Board of Directors following the election of Dr. Jay Birnbaum.